EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry

Gonzalo Botija iD, Gonzalo Galicia, Beatriz Martínez, Carmen Cuadrado, Marta Soria, Sonia Fernández, Pedro Urruzuno, María-Luz Cilleruelo, SEGHNP H. pylori Working Group

Helicobacter · 2024

DOI: 10.1111/hel.13142 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Gonzalo Botija und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Registries, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Spanish Society of Pediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the efficacy of colloidal bismuth subcitrate (CBS) therapy for the eradication of H. pylori in patients from a national pediatric registry of H. pylori infection.

Methods

The Spanish Registry of Children with H. pylori Infection (RENIHp) is a national, multi‐center, prospective, non‐interventional registry that includes children aged 5–18 years with H. pylori infection diagnosed by endoscopy. All patients in the registry who were treated with CBS between the period 2020 and 2023 were included in this study. The primary outcome was the eradication rate, which was assessed using a 13 C‐urea breath test or monoclonal antigen in the stool 6–8 weeks post‐treatment.

Results

The registry included 682 patients, 38 (5.6%) of whom underwent treatment with CBS. Fifty percent (19/38) of patients had previously undergone unsuccessful eradication treatment. In 78.9% (30/38) of patients, treatment was guided by an antibiotic sensitivity test. In the remaining patients, an empirical approach was employed. The CBS therapies used were as follows: quadruple therapy with proton pump inhibitors (PPIs), CBS, amoxicillin, and metronidazole (MET) [18/38 (47.3%)]; quadruple therapy with PPIs, CBS, tetracycline, and MET [13/38 (34.2%)]; and other therapies [7/38 (18.4%)]. Thirty‐two patients (84.2%) treated with CBS were followed‐up with eradication monitoring. The overall eradication rate in patients treated with CBS was 93.8% (30/32, [95% CI: 85.4%–100%]), whereas it was 86.7% in patients in the registry who were not on CBS treatment (430/496, [95% CI: 83.3%–89.5%], p = 0.208). In the six patients with dual resistance to clarithromycin (CLA) and MET who were treated with quadruple therapy with CBS, the eradication rate was 100% ( n = 6/6, [95% CI: 61.0%–100%]).

Conclusion

CBS therapies in our registry, although only used in selected cases and at lower than recommended levels, were very effective and showed an eradication rate of > 90%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriRegistriesAnti-Bacterial AgentsHumansChildAdolescentFemaleMaleChild, PreschoolProspective StudiesTreatment OutcomeOrganometallic CompoundsDrug Therapy, CombinationBismuthSpainProton Pump InhibitorsMetronidazoleAmoxicillinBreath Tests

Stichwörter der Autor:innen

Helicobacter pyloribismutheradication therapypediatric

Substanzen

Anti-Bacterial AgentsOrganometallic CompoundsBismuthProton Pump InhibitorsMetronidazoleAmoxicillinbismuth tripotassium dicitrate

Autor:innen und Institutionen

  • Pediatric Gastroenterology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Pediatric Gastroenterology Unit, Hospital Universitario de Guadalajara, Spain.
  • Pediatric Gastroenterology Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Pediatric Gastroenterology Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Pediatric Gastroenterology Unit, Hospital Universitario HM Montepríncipe, Madrid, Spain.
  • Pediatric Gastroenterology Unit, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain.

ORCID-Profile: Gonzalo Botija

Förderung

  • Spanish Society of Pediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP)

Zitieren

APA

Botija, G., Galicia, G., Martínez, B., Cuadrado, C., Soria, M., Fernández, S., Urruzuno, P., Cilleruelo, M. L., & SEGHNP H. pylori Working Group (2024). Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry. Helicobacter. https://doi.org/10.1111/hel.13142

Vancouver

Botija G, Galicia G, Martínez B, Cuadrado C, Soria M, Fernández S, et al. Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry. Helicobacter. 2024. doi:10.1111/hel.13142

BibTeX
@article{Botija2024,
  author = {Botija, Gonzalo and Galicia, Gonzalo and Martínez, Beatriz and Cuadrado, Carmen and Soria, Marta and Fernández, Sonia and Urruzuno, Pedro and Cilleruelo, María-Luz and SEGHNP H. pylori Working Group, SEGHNP H. pylori Working Group},
  title = {Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13142}
}
Kostenlos starten →